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Systematic Review of Prognostic Factors for Mortality in Dogs
with Immune-mediated Hemolytic Anemia
J.W. Swann and B.J. Skelly
Background: Treatment of dogs with primary immune-mediated hemolytic anemia (IMHA) is difficult and frequently
unrewarding. Prognostic factors have been evaluated in a number of previous studies, and identification of such factors
would be beneficial to enable selection of appropriate therapeutic regimens and supportive care.
Objectives: The aim of the current study was to undertake a critical appraisal of the risk of bias in evidence relating to
prognostic indicators for mortality in dogs with IMHA.
Animals: Three hundred and eighty client-owned dogs with spontaneous primary idiopathic IMHA reported in 6 previ-
ous studies.
Methods: A systematic review was conducted to evaluate evidence relating to prognostic factors for mortality in dogs
with primary IMHA. Search tools were employed to identify articles and a validated appraisal tool was used to assess the
quality of individual studies by considering inclusion and exclusion criteria, measurement of prognostic, outcome and
confounding variables, and statistical methods.
Results: Few studies evaluated prognostic indicators for IMHA in dogs, and all of these suffered from methodologic
flaws in at least 1 major area. Fifteen different variables were identified as prognostic indicators, with 2 variables identified
by >1 study.
Conclusions and Clinical Importance: There are few pieces of high-quality evidence available to enable estimation of
prognosis for dogs presenting with primary IMHA.
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Primary immune-mediated hemolytic anemia(IMHA) is the result of a spontaneous autoim-
mune response directed against antigens expressed on
the surface of erythrocytes. Production of autoreactive
antibodies is the defining event in this type 2 autoim-
mune response. Antibodies may facilitate direct intra-
vascular lysis of red blood cells or phagocytosis and
extravascular destruction by cells of the monocyte-
phagocyte system in the liver and spleen. Immune-
mediated hemolytic anemia is reported to be the most
common immune-mediated disease of dogs, and the
majority of cases are idiopathic.1
Management of IMHA is challenging, and affected
animals frequently require blood transfusions and
other forms of advanced supportive care when they
are presented acutely.2 Numerous immunosuppressive
and antithrombotic medications have been studied for
treatment of the disease, but there is no consensus
regarding the optimal regimen that should be
employed.3
Several studies have sought to identify simple prog-
nostic factors that can be measured at the point of
presentation to guide clinicians in the provision of
appropriate care. Because there appears to be a wide
spectrum of disease severity in dogs with IMHA,
establishment of valid prognostic indicators may
enable concentration of health resources on those
patients that appear to be severely affected, while
avoiding unnecessary adverse effects in patients that
are mildly affected.4,5 Recognition of heterogeneity in
the population of dogs with primary IMHA using sim-
ilar prognostic indicators also is likely to be important
in future studies assessing the efficacy of therapeutic
interventions.2
To facilitate systematic evaluation of the risk of bias
in studies of prognostic factors, Hayden et al6 devel-
oped the Quality in Prognosis Studies (QUIPS) tool,
which contains 30 questions arranged into 6 domains
to provide a comprehensive assessment of the quality
of a study. As validation, this tool has been used in
more than 80 reviews of prognostic studies in various
areas of human medicine, and a recent review of stud-
ies that used the QUIPS tool demonstrated good
agreement among reviewers and showed that reviewers
found the tool simple to use.7
The aim of the current study was to systematically
evaluate the current evidence relating to identification
of prognostic factors for mortality in dogs with
primary IMHA by using the QUIPS tool.
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Materials and Method
Search Strategy
The online databases of PubMed, ISI Web of Science, and
CAB Abstracts were searched from 1980 to October 2013
using the following search terms: (dog OR dogs OR canis OR
canine OR canidae) AND (IMHA OR AIHA OR hemolytic
anemia OR hemolysis OR immune-mediated hemolytic ane-
mia). Variants of the search terms also were used to account for
possible differences in spelling of the major keywords, and all
searches were conducted on 31st October 2013. The records of
articles identified were transferred to a bibliographic software pack-
age,a and duplicates were removed. The titles and abstracts of arti-
cles were scanned by the primary author to identify those of
relevance, and the full text of these studies was obtained. Articles
that were not published in English were translated to enable
assessment. Selection of articles was not performed in a blinded
manner because the primary author is familiar with literature per-
taining to IMHA in dogs.
Inclusion and Exclusion Criteria
For inclusion in the review, studies were required to fulfill the
following 4 inclusion criteria:
● Study presented primary data from client-owned dogs with
spontaneous disease
● Study was published as a complete report in a peer-
reviewed journal
● Study evaluated prognostic indicators for mortality using
data collected from dogs with primary IMHA
● Study used multivariable analysis to assess potential prog-
nostic factors and exclude confounding factors
Where data from the same group of animals were used to produce
>1 article, only the study reporting data from the largest number of
animals was included. Studies also were excluded if the investigation
of prognostic factors was not related to outcome measures of mor-
tality.
Critical Appraisal
Studies were evaluated independently by each of the authors
using the QUIPS tool developed by Hayden et al.6,7 This tool con-
sists of 30 questions divided into 6 key domains, and several of the
questions were modified by the authors for this study. The com-
plete tool used for assessment is shown in Table S1. The authors
completed the assessment for each study and assigned a grade of
low, moderate or high risk of bias for each domain. Where differ-
ences were identified between the authors of this paper, these were
resolved by consensus.
A j score was calculated to determine the degree of interob-
server variability for initial scoring8 by comparing the number of
domains scored as low or moderate risk of bias in each study. A
commercially available software package was used to conduct
this analysis.b
Reporting of Results
Variation in specific outcome measures and definitions of
prognostic factors among studies precluded quantitative synthesis
of results. Relevant information from each study was abstracted
into tabular format and major conclusions were described. The
principal summary measure was the final multivariable model
with the hazard or odds ratio and confidence intervals for each
variable. Additional information collected included numbers of
animals included in the multivariable analysis, years of data col-
lection, demographic characteristics of the study population, sta-
tistical methods employed, and definition of the outcome
measure(s) relating to mortality. The review was presented
according to the PRISMA template9 for reporting of systematic
reviews.
Results
Search techniques identified 1,640 records, of which
6 (0.4%) were selected for inclusion in the review.10–16
Reasons for exclusion of the remaining studies are
shown in Figure 1.
Study Characteristics
The articles included in the study used data from
380 dogs with primary IMHA to produce models
investigating prognostic factors for mortality, with a
median sample size of 56 (range, 20–222). The studies
reported data from dogs that were presented for treat-
ment of IMHA between 1988 and 2010. Two studies
collected data prospectively,15,16 whereas 4 studies were
retrospective cohort studies. Study populations were
based in the Netherlands (n = 2), United Kingdom (2),
United States (1), and Japan (1).
Fig 1. Summary of recruitment process for studies.
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The characteristics of the study populations
described in each article are shown in Table 1. Two
studies provided incomplete demographic data relating
to the animals that were recruited.14,15
Assessment of Quality
The results of systematic review of evidence quality
are shown in Table 2. None of the studies had a high
risk of bias in domains assessing measurement of
prognostic factors or outcome variables, but high
risks of bias were observed in all other domains for
at least 1 study. Two studies had a low risk of bias in
≥1 domains,10,15 whereas each of the others had a
high risk of bias in at least 1 domain. The j score for
interobserver agreement was 0.7 (standard error, 0.3).
Prognostic Factors
A summary of the major findings of each study is
shown in Table 3. Fifteen different prognostic factors
were identified, with 2 factors (serum bilirubin and
urea or blood urea nitrogen concentrations) each iden-
tified by 2 different studies. Cox proportional hazards
analysis was employed in 5 studies using actual sur-
vival times, and multivariable logistic regression with
an endpoint of mortality at 30 days after presentation
was used in the remaining study.
Table 1. Demographic data abstracted from articles included in review.
References
N
Time Period Setting Country Age (years) Sex Breed
With
Primary
IMHA
Included in
Multivariable
Analysis (%)
Piek et al10 222 164 (73.9) Jan 1994–Dec
2000
and Jan
2002–Dec 2005
Tertiary
referral
hospital
Netherlands Separate data
presented for
2 treatment
groups: 1:
(n = 149)
median:
5.7, range:
0.3–13.9;
2: (n = 73)
median:
4.6, range:
0.4–12.7
68 ME
20 MN
73 FE
61 FN
43 breeds,
Most
common:
Cross-breed
(n = 26), cocker
spaniel (11),
old English
sheepdog (9)
Ishihara
et al12
71 * Apr 1997–
Mar 2006
Tertiary
referral
hospital
Japan Mean 6.2,
median 6.4,
range: 0.5–14.2
24 ME
9 MN
27 FE
11 FN
23 breeds. Most
common: shih
tzu (n = 17),
cocker spaniel
(7), Welsh
corgi (6)
Reimer et
al13
70 * Jan 1988–
Feb 1996
Tertiary
referral
hospital
United
States
Median 6,
range: 1–13
49 M
21 F
Most common:
cross-breed
(n = 12), cocker
spaniel (11),
poodle (7)
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42 34 (81.0) 2002–2010 Tertiary
referral
hospital
United
Kingdom
* * 23 breeds. Most
common:
cocker spaniel
(n = 8),
Labrador
retriever (6)
Piek et al15 24 21 (87.5) Sep 2007–
Oct 2008
Tertiary
referral
hospital
Netherlands * 9 ME
2 MN
3 FE
10 FN
*
Kjelgaard-
Hansen
et al16
20 * Oct 2008–
Oct 2009
Tertiary
referral
hospital
United
Kingdom
Mean 7.2,
SD  2.9
2 ME
1 MN
2 FE
15 FN
11 breeds. Most
common:
English
springer spaniel
(n = 6), cocker
spaniel (3),
Labrador
retriever (2)
*Not stated. M(E/N): male (entire/neutered), F(E/N): female (entire/neutered).
Prognostic Factors for Mortality in IMHA 9
Discussion
The aim of this review was to assess the risk of
bias in studies investigating prognostic factors for
mortality in dogs with primary IMHA. A small
number of studies have evaluated prognostic factors
for mortality in dogs with primary IMHA using
appropriate methods to exclude potential confound-
ing factors, and a high or moderate risk of bias was
identified in at least 1 area of each of these studies
Table 2. Results of quality assessment of studies included in review.
Table 3. Prognostic factors for mortality identified by studies included in review.
References Study Design
Outcome
Measure
Statistical
Method
Prognostic Factors Identified
Factor OR/HR 95% CI
Piek et al10 Retrospective
cohort
Survival time
(death because
of IMHA)
Cox
proportional
hazards
analysis
Serum [urea] (>56 mg/dL) 2.56 1.729–3.789
Icterus 2.94 1.60–5.42
Spherocytosis 0.38 0.20–0.72
Ishihara et al12 Retrospective
cohort
Survival time
(death because
of IMHA)
Cox
proportional
hazards
analysis
Sex (male) 1.59 *
Season (warm) 1.68 *
PCV (<20%) 1.56 *
Platelet count (<200,000/lL) 1.63 *
Total protein (<6 g/dL) 1.78 *
Reimer et al13 Retrospective
cohort
Survival time
(all-cause
mortality)
Cox
proportional
hazards
analysis
Serum [bilirubin] * *
Serum ALP activity * *
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Retrospective
cohort
Survival time
(all-cause
mortality)
Cox
proportional
hazards
analysis
Serum [urea] 1.211 1.073–1.367
Serum [bilirubin] 1.014 1.003–1.024
Piek et al15 Prospective
cohort
Survival time
(death because
of IMHA)
Cox
proportional
hazards
analysis
Serum [creatinine] (>0.23 mg/dL) 1.15 1.00–1.35
Monocyte count (>100/lL) 2.32 1.34–6.05
APTT 1.12 1.03–1.26
Kjelgaard-
Hansen16
Prospective
cohort
Mortality at
30 days (all-
cause
mortality)
Multivariable
logistic
regression
IL-18 * *
MCP-1 * *
OR, odds ratio; HR, hazard ratio; CI, confidence interval; APTT, activated partial thromboplastin time; PCV, packed cell volume;
ALP, alkaline phosphatase; IL-18, interleukin 18; MCP-1, monocyte chemoattractant protein 1.
*Not stated.
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using a validated quality assessment tool. Several dif-
ferent prognostic factors were identified in different
study populations, with 2 factors identified by >1
investigation.
Of the large numbers of studies evaluated for inclu-
sion in this review, only 6 ultimately were selected.
The small number of studies available for review
reflects a paucity of published evidence relating to the
natural history of canine IMHA in particular and dis-
eases of dogs in general.17
In common with published scientific literature
relating to the treatment of IMHA,3 studies evaluat-
ing prognostic factors for mortality were subject to
high or moderate risks of bias in at least 1 domain.
This apparent lack of quality did not relate to basic
study design, however, because retrospective cohort
studies represent an effective way to evaluate prog-
nostic factors.18 Instead, the risk of bias related
chiefly to failure to report important characteristics
of the study population, failure to report methods
used to exclude potential confounding factors, and
incomplete description of prognostic models.
Study Population
Four studies12–15 reported inclusion criteria that
were not considered reliable for diagnosis of primary
IMHA, increasing the risk of bias associated with
case selection. In particular, 3 studies12,13,15 failed to
report procedures that were used to exclude underly-
ing causes of IMHA in dogs presenting with evi-
dence of hemolytic anemia, such as thoracic and
abdominal imaging and appropriate tests for infec-
tious agents. In 2 instances,13,14 the diagnosis of
IMHA could have been based on clinical evidence of
hemolysis, whereas we consider tests that identify the
presence of antibodies specific for erythrocyte anti-
gens (eg, saline agglutination test, observation of
spherocytes on a blood smear, Coombs’ test) essen-
tial for a confident diagnosis of the disease.1,2
Excluded Cases
Only 1 study10 reported details of the group of ani-
mals that were not included and the reasons for exclu-
sion. Evaluation of this group of animals is important
to ensure that cases with certain characteristics that
may have prognostic relevance, such as more severe
anemia, have not been excluded from the analysis.
Information regarding cases that have not been
included rarely is presented in retrospective studies in
the veterinary literature, but this information also
would be helpful to determine whether studies have
reported data from representative samples of animals.
Prognostic Factors
Prognostic factors generally were well-described and
appropriate for dogs with IMHA, but these differed
widely among studies, and methods of measurement
were not always stated explicitly. Most variables
considered were laboratory parameters that can be
measured consistently across multiple centers, although
1 study included the presence of icterus,10 which is a
subjective judgment that may differ among individuals.
The majority of studies reported prognostic factors
that are widely measured in general practice, but 1
study evaluated the cytokines IL-18 and MCP-1,16
which are unlikely to be measured outside of a
research environment.
One study12 included season of presentation as a
prognostic factor. Previous studies have reported
conflicting results regarding the seasonal incidence of
IMHA, with some reporting a higher incidence in
warmer months19,20 and others showing no associa-
tion.14,21–23 Suggested reasons for the apparent
association include the effect of environmental
temperature on immune responses, greater risk of
dehydration or respiratory distress in warmer
months, and the potential effect of an undetected
infectious agent, which raises concern that some of
the cases reported by Ishihara and others12 may
have suffered from IMHA secondary to an infectious
disease process.
Hazard and odds ratios were of small magnitude for
most of the factors identified, and the clinical relevance
of these factors therefore is questionable. Interestingly,
ratios derived from studies that evaluated the same vari-
ables as single prognostic factors19,24,25 often were of
much greater magnitude, suggesting that confounding
factors may have a considerable effect on variables such
as serum bilirubin concentration. Because of the small
number of cases included in many of the studies, confi-
dence intervals also were wide, and the true clinical valid-
ity of each prognostic factor therefore is difficult to
estimate.
Confounding Factors
Articles were excluded if they did not evaluate
potential confounding factors in the context of a mul-
tivariable model, either by Cox proportional hazards
analysis or multivariable logistic regression. Although
many more studies have evaluated prognostic factors
for mortality in IMHA, these typically only considered
individual factors without accounting for the effects of
multiple variables. These studies were considered unre-
liable because dogs with IMHA often are systemically
ill and showing evidence of dysfunction in multiple
organs, and variations in individual biochemical and
hematologic variables may be spuriously associated
with survival times.
The studies included in this review mainly considered
hematologic, biochemical, and clinical variables as
potential prognostic factors, but the exact factors eval-
uated in each model were not stated in a number of
studies. One study selected potential confounding fac-
tors on the basis of previous evidence, but important
factors, such as severity of anemia, were not included.16
Several of the studies evaluated the effect of different
treatment protocols on survival, but did not consider
this variable in subsequent prognostic models.12–16
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These observations highlight the importance of rational
selection of variables for inclusion in multivariable
models. Use of a small number may omit factors that
have an important modifying or confounding effect,
but inclusion of too many factors may increase the risk
of spurious associations or correlations among similar
variables, or the risk of overfitting multivariable
models.18
Outcome Measures
As with studies of therapeutic regimens in dogs
with IMHA,3 outcome measures varied widely, and
the duration of follow-up periods was not stated in
any of the reports. Furthermore, only 3 studies10,12,15
used death caused by IMHA for development of the
prognostic model and the remainder used all-cause
mortality. Conclusions drawn using each of these
outcome measures will differ markedly in their clini-
cal relevance. Losses to follow-up were described in
2 studies,13,14 but the impact of these cases on model
building was not considered in any of the investiga-
tions.
Statistical Methods
The purpose of this review was not to provide a
detailed critique of statistical techniques employed
when building prognostic models, because this pro-
cess has been described elsewhere.4,26 Nevertheless,
there was considerable variation in the strategies
used to construct these models, and numerous defi-
ciencies were observed. Models frequently were con-
structed with large numbers of prognostic factors
evaluated in samples that had low event rates. There
are no concrete rules for building models, but it is
often stated that 10 events should be available for
every prognostic factor that is included so that the
final model is not distorted by spurious associa-
tions.27 Three studies did not report data necessary
to evaluate the importance of an association, such as
the hazard or odds ratio and its confidence inter-
val.12,13,16
Although Cox proportional hazards analysis is an
effective strategy for identification of prognostic fac-
tors, it relies on availability of complete survival
data for a large proportion of the cases included,
and final results may not be representative if largely
based on right-censored data. Some of the studies
reported here appeared to rely on automated model
building algorithms provided by statistical software
programs, whereas optimal strategies are likely to
take account of many more factors, such as a priori
importance of variables and changes in model
parameters when single variables are added or
removed. Only 2 of the studies reported the use of
diagnostic tests to evaluate the adequacy-of-fit and
predictive capabilities of the model produced,10,15
and none subjected their model to the gold standard
test: validation in an independent sample of dogs
with IMHA.28,29
Limitations
This review included only studies that used multivari-
able models to evaluate prognostic factors for IMHA,
which led to the exclusion of many studies that investi-
gated single factors. This design may have excluded a
large amount of information regarding prognostic fac-
tors for IMHA, but we considered this to be an impor-
tant criterion for selection of studies with valid results.
The review also excluded reports of studies that were
not published in peer-reviewed journals because we
believed abstracts did not provide sufficient methodo-
logic detail to evaluate studies as compared to complete
published reports. Despite attempts to appraise studies
in an objective and consistent manner, use of the QUIPS
tool involves subjective judgement in assigning a score
for each of the 6 domains. Because specific criteria were
provided for most of the 30 questions forming the
appraisal tool, we consider this subjective component to
be minimal, and calculation of interobserver j value
showed good consistency between the 2 evaluators.
Practical Applications
Identification of prognostic factors was used to pro-
duce a clinical score in 1 instance,12 but this model
included sex and season of presentation as factors, and
we are unsure why these variables should be important
prognostic factors. The approach used in this study,
however, has the potential to be practically useful by
allowing the clinician to calculate a simple score on
presentation. Similar scores, including the survival pre-
diction index (SPI) and acute patient physiologic and
laboratory evaluation (APPLE) scores, have been
developed in studies of animals admitted to veterinary
intensive care units to guide clinical interventions and
provide a global indicator of illness severity in research
studies.30,31
Of the other studies considered here, 3 identified
icterus or hyperbilirubinemia as a significant prog-
nostic factor, and Piek et al11 reported a consider-
able effect size for development of icterus.
Hyperbilirubinemia may represent a simple, widely
available indicator of prognosis if it performs well
alongside more complete models, but previous work
also suggests that there could be considerable over-
lap in serum bilirubin concentrations between dogs
that died while hospitalized and those that were dis-
charged.14
Conclusion
Measurement and evaluation of prognostic factors
has the potential to improve the clinical management of
cases of IMHA in dogs and to allow resources to be tar-
geted appropriately. Although several prognostic factors
were identified in the studies considered in this review,
effect sizes generally were small when potential con-
founding factors were taken into consideration, and
none of the prognostic models has undergone external
validation. Variable methodology and reporting further
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emphasize the need for standardized definitions and col-
laborative research in this field in the future.
Footnotes
a EndNote X5 (Thomson Reuters Philadelphia, PA)
b IBM Corp. Released 2011, IBM SPSS Statistics for Windows,
Version 20.0.; IBM Corp, Armonk, NY
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